• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
In-Hospital Mortality Risk Factor Analysis in Multivessel Percutaneous Coronary Intervention Inpatient Recipients in the United States.美国多支血管经皮冠状动脉介入治疗住院患者的院内死亡风险因素分析
Cureus. 2021 Aug 28;13(8):e17520. doi: 10.7759/cureus.17520. eCollection 2021 Aug.
2
Multivessel Percutaneous Coronary Interventions in the United States: Insights From the Nationwide Inpatient Sample.美国的多支血管经皮冠状动脉介入治疗:来自全国住院患者样本的见解
Angiology. 2016 Apr;67(4):326-35. doi: 10.1177/0003319715593853. Epub 2015 Jul 5.
3
Comparison of In-Hospital Mortality, Length of Stay, Postprocedural Complications, and Cost of Single-Vessel Versus Multivessel Percutaneous Coronary Intervention in Hemodynamically Stable Patients With ST-Segment Elevation Myocardial Infarction (from Nationwide Inpatient Sample [2006 to 2012]).血流动力学稳定的ST段抬高型心肌梗死患者单支血管与多支血管经皮冠状动脉介入治疗的院内死亡率、住院时间、术后并发症及费用比较(来自全国住院患者样本[2006年至2012年])
Am J Cardiol. 2016 Oct 1;118(7):950-8. doi: 10.1016/j.amjcard.2016.06.057. Epub 2016 Jul 18.
4
Nationwide trends in the utilization of multivessel percutaneous coronary intervention (MVPCI) in the United States across different gender and ethnicities.美国不同性别和种族的多血管经皮冠状动脉介入治疗(MVPCI)的利用情况的全国性趋势。
J Interv Cardiol. 2009 Jun;22(3):247-51. doi: 10.1111/j.1540-8183.2009.00467.x. Epub 2009 Apr 14.
5
Is multivessel intervention in ST-elevation myocardial infarction associated with early harm? Insights from observational data.ST段抬高型心肌梗死的多支血管介入治疗与早期损害有关吗?来自观察性数据的见解。
Catheter Cardiovasc Interv. 2016 Nov;88(5):697-707. doi: 10.1002/ccd.26643. Epub 2016 Jun 24.
6
Racial and sex disparities in resource utilization and outcomes of multi-vessel percutaneous coronary interventions (a 5-year nationwide evaluation in the United States).多支血管经皮冠状动脉介入治疗中资源利用及治疗结果的种族和性别差异(美国一项为期5年的全国性评估)
Cardiovasc Diagn Ther. 2019 Feb;9(1):18-29. doi: 10.21037/cdt.2018.09.02.
7
Decline in the nationwide trends in in-hospital mortality of patients undergoing multivessel percutaneous coronary intervention.接受多支血管经皮冠状动脉介入治疗患者的院内死亡率在全国范围内呈下降趋势。
J Invasive Cardiol. 2009 Aug;21(8):388-90.
8
Variation in utilization of multivessel percutaneous coronary intervention: influence of hospital volume.多支血管经皮冠状动脉介入治疗使用情况的差异:医院手术量的影响
Coron Artery Dis. 2015 Dec;26(8):657-64. doi: 10.1097/MCA.0000000000000298.
9
Utilization of Left Ventricular Assist Device for Congestive Heart Failure: Inputs on Demographic and Hospital Characterization From Nationwide Inpatient Sample.左心室辅助装置在充血性心力衰竭中的应用:来自全国住院患者样本的人口统计学和医院特征数据
Cureus. 2021 Jul 1;13(7):e16094. doi: 10.7759/cureus.16094. eCollection 2021 Jul.
10
Outcomes of culprit versus multivessel PCI in patients with multivessel coronary artery disease presenting with ST-elevation myocardial infarction complicated by shock.多支冠状动脉疾病合并ST段抬高型心肌梗死并发休克患者罪犯血管PCI与多支血管PCI的结局
J Invasive Cardiol. 2013 May;25(5):218-24.

引用本文的文献

1
Multivessel vs. culprit vessel-only percutaneous coronary intervention in ST-segment elevation myocardial infarction with and without cardiogenic shock.多支血管与仅罪犯血管行经皮冠状动脉介入治疗在伴或不伴心源性休克的ST段抬高型心肌梗死中的应用
Front Cardiovasc Med. 2022 Nov 24;9:992456. doi: 10.3389/fcvm.2022.992456. eCollection 2022.

本文引用的文献

1
Does multivessel revascularization fit all patients with STEMI and multivessel coronary artery disease? A systematic review and meta-analysis.多支血管血运重建适用于所有ST段抬高型心肌梗死和多支冠状动脉疾病患者吗?一项系统评价和荟萃分析。
Int J Cardiol Heart Vasc. 2021 Jun 11;35:100813. doi: 10.1016/j.ijcha.2021.100813. eCollection 2021 Aug.
2
Comparison of Long-Term Clinical Outcome Between Multivessel Percutaneous Coronary Intervention Versus Infarct-Related Artery-Only Revascularization for Patients With ST-Segment-Elevation Myocardial Infarction With Cardiogenic Shock.ST 段抬高型心肌梗死伴心原性休克患者行多支血管经皮冠状动脉介入治疗与梗死相关动脉血运重建的长期临床结局比较。
J Am Heart Assoc. 2019 Dec 17;8(24):e013870. doi: 10.1161/JAHA.119.013870. Epub 2019 Dec 10.
3
Impact of Late Ventricular Arrhythmias on Cardiac Mortality in Patients with Acute Myocardial Infarction.急性心肌梗死后室性心律失常对心脏死亡率的影响。
J Interv Cardiol. 2019 Jul 8;2019:5345178. doi: 10.1155/2019/5345178. eCollection 2019.
4
Racial and sex disparities in resource utilization and outcomes of multi-vessel percutaneous coronary interventions (a 5-year nationwide evaluation in the United States).多支血管经皮冠状动脉介入治疗中资源利用及治疗结果的种族和性别差异(美国一项为期5年的全国性评估)
Cardiovasc Diagn Ther. 2019 Feb;9(1):18-29. doi: 10.21037/cdt.2018.09.02.
5
Revascularization Strategies in Cardiogenic Shock Patients With MVD: For Now, Keep it Simple.多支血管病变的心源性休克患者的血运重建策略:目前,保持简单化。
J Am Coll Cardiol. 2018 Feb 27;71(8):857-859. doi: 10.1016/j.jacc.2017.12.026.
6
Coronary surgery in elderly: it is never too late.老年患者的冠状动脉手术:永远不会太晚。
J Thorac Dis. 2016 Dec;8(12):E1641-E1643. doi: 10.21037/jtd.2016.12.34.
7
Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.《2017年心脏病和中风统计数据更新:美国心脏协会报告》
Circulation. 2017 Mar 7;135(10):e146-e603. doi: 10.1161/CIR.0000000000000485. Epub 2017 Jan 25.
8
Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial.急性ST段抬高型心肌梗死合并多支血管病变患者行直接经皮冠状动脉介入治疗时完全血运重建与仅对罪犯病变血运重建的随机试验:CvLPRIT试验
J Am Coll Cardiol. 2015 Mar 17;65(10):963-72. doi: 10.1016/j.jacc.2014.12.038.
9
Hormone therapy for preventing cardiovascular disease in post-menopausal women.激素疗法预防绝经后女性心血管疾病
Cochrane Database Syst Rev. 2015 Mar 10;2015(3):CD002229. doi: 10.1002/14651858.CD002229.pub4.
10
Short- and long-term cause of death in patients treated with primary PCI for STEMI.ST段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗的短期和长期死因。
J Am Coll Cardiol. 2014;64(20):2101-8. doi: 10.1016/j.jacc.2014.08.037. Epub 2014 Nov 10.

美国多支血管经皮冠状动脉介入治疗住院患者的院内死亡风险因素分析

In-Hospital Mortality Risk Factor Analysis in Multivessel Percutaneous Coronary Intervention Inpatient Recipients in the United States.

作者信息

Tummala Ravi, Shah Suchi D, Rawal Era, Sandhu Ramneek K, Kavuri Swathi P, Kaur Gagan, Khan Asma T, Mathialagan Keerthika, Ajibawo Temitope

机构信息

Internal Medicine, Narayana Medical College, Nellore, IND.

Internal Medicine, Ahmedabad Municipal Corporation's Medical Education Trust Medical College, Ahmedabad, IND.

出版信息

Cureus. 2021 Aug 28;13(8):e17520. doi: 10.7759/cureus.17520. eCollection 2021 Aug.

DOI:10.7759/cureus.17520
PMID:34603890
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8476197/
Abstract

Objectives The primary goal of our study is to evaluate the mortality rate in inpatient recipients of multivessel percutaneous coronary intervention (MVPCI) and to evaluate the demographic risk factors and medical complications that increase the risk of in-hospital mortality. Methods We conducted a cross-sectional study using the Nationwide Inpatient Sample (NIS, 2016) and included 127,145 inpatients who received MVPCI as a primary procedure in United States' hospitals. We used a multivariable logistic regression model adjusted for demographic confounders to measure the odds ratio (OR) of association of medical complications and in-hospital mortality risk in MVPCI recipients. Results The in-hospital mortality rate was 2% in MVPCI recipients and was seen majorly in older-age adults (>64 years, 74%) and males (61%). Even though the prevalence of mortality among females was comparatively low, yet in the regression model, they were at a higher risk for in-hospital mortality than males (OR 1.2; 95% CI 1.13-1.37). While comparing ethnicities, in-hospital mortality was prevalent in whites (79%) followed by blacks (9%) and Hispanics (7.5%). Patients who developed cardiogenic shock were at higher odds of in-hospital mortality (OR 9.2; 95% CI 8.27-10.24) followed by respiratory failure (OR 5.9; 95% CI 5.39-6.64) and ventricular fibrillation (OR 3.5; 95% CI 3.18-3.92). Conclusion Accelerated use of MVPCI made it important to study in-hospital mortality risk factors allowing us to devise strategies to improve the utilization and improve the quality of life of these at-risk patients. Despite its effectiveness and comparatively lower mortality profile, aggressive usage of MVPCI is restricted due to the periprocedural complications and morbidity profile of the patients.

摘要

目的 我们研究的主要目标是评估多支血管经皮冠状动脉介入治疗(MVPCI)住院患者的死亡率,并评估增加住院死亡率风险的人口统计学危险因素和医学并发症。方法 我们使用全国住院患者样本(NIS,2016)进行了一项横断面研究,纳入了127145例在美国医院接受MVPCI作为主要手术的住院患者。我们使用了一个针对人口统计学混杂因素进行调整的多变量逻辑回归模型,以测量MVPCI接受者中医学并发症与住院死亡风险关联的比值比(OR)。结果 MVPCI接受者的住院死亡率为2%,主要见于老年人(>64岁,74%)和男性(61%)。尽管女性的死亡率相对较低,但在回归模型中,她们的住院死亡风险高于男性(OR 1.2;95% CI 1.13 - 1.37)。在比较不同种族时,住院死亡率在白人中最为普遍(79%),其次是黑人(9%)和西班牙裔(7.5%)。发生心源性休克的患者住院死亡几率更高(OR 9.2;95% CI 8.27 - 10.24),其次是呼吸衰竭(OR 5.9;95% CI 5.39 - 6.64)和心室颤动(OR 3.5;95% CI 3.18 - 3.92)。结论 MVPCI的加速应用使得研究住院死亡风险因素变得很重要,这使我们能够制定策略来提高这些高危患者的利用率并改善其生活质量。尽管MVPCI有效且死亡率相对较低,但由于围手术期并发症和患者的发病情况,其积极应用受到限制。